Factors associated with seeking and receiving home antiviral therapy during the coronavirus disease 2019 (COVID-19) pandemic
Rattachement africain : us, au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Home antiviral treatment (HAVT: nirmatrelvir/ritonavir [Paxlovid] and molnupiravir [Lagevrio]) for COVID-19 was approved in December 2021 by the U.S. Food and Drug Administration, but ensuing utilization during the Coronavirus Disease 2019 (COVID-19) pandemic was low. Factors associated with seeking HAVT treatment have not been fully explored. Study design: Cross-sectional survey of 9944 U.S. adults to identify factors associated with seeking and receiving HAVT in persons with confirmed or suspected COVID-19. Results: COVID-19 infection was confirmed or suspected in 4,355 (43.8%) participants. HAVT was sought by 1,331 (30.6%) and medication was received by 928 (21.3%). In comparison to those who were COVID-19 test negative and had no loss of taste or smell, the factor most associated with seeking HAVT was a loss of taste or smell irrespective of a positive (aOR: 3.823, 95% C.I. 2.626-5.567) or negative COVID-19 test (aOR: 3.306; 95% C.I. 2.086-5.241). Similarly, loss of taste or smell was strongly associated with receiving HAVT. Male sex, younger age, Black race, Hispanic ethnicity, conservative or liberal political preference, and medical discrimination were some of the other factors associated with a greater likelihood of seeking HAVT. Barriers to obtaining treatment included feeling uncomfortable obtaining HAVT while sick and lack of transportation; 14.7% of those seeking treatment reported at least one barrier. Conclusion: In a general population, HAVT was an underutilized resource during the COVID-19 pandemic. Loss of taste or smell was the most important factor among several others associated with seeking HAVT irrespective of COVID-19 test status. Supplementary Information: The online version contains supplementary material available at 10.1186/s12982-025-01192-3.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Factors associated with seeking and receiving home antiviral therapy during the coronavirus disease 2019 (COVID-19) pandemic
- Date Crossref
- 08/12/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Brigham and Women's Hospital Division of Sleep and Circadian Disorders pays non établi dans la noticeÉtablissement de santé
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Institute for Breathing and Sleep pays non établi dans la noticeOrganisation à but non lucratif
-
Robert S. Peabody Museum of Archaeology pays non établi dans la noticeInstitution
-
Austin Health pays non établi dans la noticeÉtablissement de santé
-
Monash University Turner Institute for Brain and Mental Health pays non établi dans la noticeUniversité ou école supérieure
-
La Trobe University pays non établi dans la noticeUniversité ou école supérieure
-
The University of Melbourne Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Division of Sleep Medicine pays non établi dans la noticeInstitution
-
Francis Weld Peabody Society pays non établi dans la noticeInstitution
-
School of Psychological Sciences pays non établi dans la noticeUniversité ou école supérieure
-
University Department of Rural Health pays non établi dans la noticeUniversité ou école supérieure
Division of Sleep and Circadian Disorders — Brigham and Women's Hospital, Harvard University et Institute for Breathing and Sleep, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.